Nurses Performed Colposcopies Effectively in Low-Resource Areas


Nurses trained in the visual inspection with acetic acid cervical cancer screening method were able to successfully perform colposcopy and detect cervical lesions.

Nurses trained in the visual inspection with acetic acid (VIA) cervical cancer screening method were able to successfully perform colposcopy and detect cervical lesions using the Swede score system, according to the results of a study published in BMJ.

According to researchers led by Ashrafun Nessa, PhD, of the department of obstetrics and gynecology at Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, this “task-shifting” from highly-qualified specialists to the least specialized professional skilled at safely and reliably performing the task could aid the 266,000 women in low-resource settings who die from cervical cancer each year.

“There is now an opportunity for policymakers to reduce the human resource gap by organizing training programs for educating nurse colposcopists and outreach see-and-treat in low-resource settings, and to promote and evaluate such programs in adequately powered researchers studies,” Nessa and colleagues wrote.

According to the study, mortality rates of cervical cancer are much higher in less developed areas of the world, and women in these low-resource settings often do not have access to national screening programs. In some of these areas, VIA by trained nurses and doctors has been implemented as a low-cost cervical cancer screening method. Women who are VIA positive are referred for colposcopy.

“In high-resource settings, nurse colposcopists have been trained to increase accessibility to colposcopy and achieve similar diagnostic accuracy as doctors, and a similar approach in low-resource settings, with diagnosis and screening by the portable battery-driven colposcope, the Gynocular, could offer an accurate, cost-effective and pragmatic approach to combat cervical cancer,” the researchers wrote.

In this study, the researchers enrolled 932 women attending a colposcopy clinic in Bangladesh who were classified as VIA naive or VIA positive (referred from another site). Prior to the study, VIA nurses were trained in colposcopy and in the Swede score system, which assigns patients a number from zero to two for each of five colposcopic variables (acetowhiteness, margins plus surface, vessel pattern, lesion size and iodine staining). Patients were randomly assigned to undergo colposcopy with either stationary colposcope or the Gynocular, a portable battery-driven colposcope.

Results showed no significant difference in tabulating Swede score between doctors and VIA trained nurses, or between the use of the stationary or Gynocular colposcope.

Based on these results, the researchers concluded that “training of nurses on colposcopy and the use of the Gynocular could have a widespread effect in reducing the number of women dying from cervical cancer, which in turn could have a major impact on community structure and wealth.”

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Related Content